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Abstract
Background: Whole exome sequencing studies identify hundreds to thousands of rare protein coding variants of
ambiguous significance for human health. Computational tools are needed to accelerate the identification of
specific variants and genes that contribute to human disease.
Results: We have developed the Variant Effect Scoring Tool (VEST), a supervised machine learning-based classifier,
to prioritize rare missense variants with likely involvement in human disease. The VEST classifier training set
comprised ~ 45,000 disease mutations from the latest Human Gene Mutation Database release and another
~45,000 high frequency (allele frequency >1%) putatively neutral missense variants from the Exome Sequencing
Project. VEST outperforms some of the most popular methods for prioritizing missense variants in carefully
designed holdout benchmarking experiments (VEST ROC AUC = 0.91, PolyPhen2 ROC AUC = 0.86, SIFT4.0 ROC AUC
= 0.84). VEST estimates variant score p-values against a null distribution of VEST scores for neutral variants not
included in the VEST training set. These p-values can be aggregated at the gene level across multiple disease
exomes to rank genes for probable disease involvement. We tested the ability of an aggregate VEST gene score to
identify candidate Mendelian disease genes, based on whole-exome sequencing of a small number of disease
cases. We used whole-exome data for two Mendelian disorders for which the causal gene is known. Considering
only genes that contained variants in all cases, the VEST gene score ranked dihydroorotate dehydrogenase
(DHODH) number 2 of 2253 genes in four cases of Miller syndrome, and myosin-3 (MYH3) number 2 of 2313
genes in three cases of Freeman Sheldon syndrome.
Conclusions: Our results demonstrate the potential power gain of aggregating bioinformatics variant scores into
gene-level scores and the general utility of bioinformatics in assisting the search for disease genes in large-scale
exome sequencing studies. VEST is available as a stand-alone software package at http://wiki.chasmsoftware.org
and is hosted by the CRAVAT web server at http://www.cravat.us
Background
The identification of mutations and genes underlying
human genetic disease continues to be a very active area
of research. Advances in DNA sequencing technology
have made it possible to rapidly identify all genetic variants
in an individual exome. This large-scale enumeration of
variants poses considerable difficulty for the identification
of disease-causing variants, as they must be singled out
from among a large pool of candidates.
Rare non-synonymous single nucleotide variants (NS-
SNVs) that alter protein sequence are particularly strong
candidates for disease-causing variants [1-3]. Experimen-
tal assessment of protein activity for mutated proteins is
very difficult, and is further impeded by the large num-
ber of NS-SNVs revealed by exome sequencing studies;
in general, sequencing identifies 3000 - 6000 NS-SNVs
per exome. This has motivated the development of
many statistical and computational methods for evaluat-
ing the functional impact of non-synonymous changes
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on proteins. The methods fall broadly into two cate-
gories, those that score mutations on the basis of biolo-
gical principles (SIFT [4], MutationAssessor [5], MAPP
[6], PANTHER [7], among others), and methods that
use existing knowledge about the functional effects of
mutations in the form a training set for supervised
machine learning (PolyPhen2 [8], SNAP [9], SNPs3D
[10], MutPred [11], MutationTaster [12], among others)
[3]. These methods are known to perform well at distin-
guishing Mendelian disease mutations from common
single nucleotide polypmorphisms [13] and usually offer
either a numeric score that represents the predicted
functional impact of an amino acid substitution, or a
probability that the substitution is deleterious to the
protein. Mutation scores can be used to substantially
reduce the number of candidate disease-causing muta-
tions detected in exome sequencing studies, but addi-
tional evidence is still needed to identify the causal
mutation unequivocally. One recent strategy that has
had considerable success in identifying both causal
genes and mutations underlying Mendelian disorders is
to assess several disease exomes together in order to
reduce the number of candidate disease genes. Sequen-
cing several exomes from unrelated individuals with the
same Mendelian disorder can substantially reduce the
list of candidate mutations/genes since all cases are
expected to result from mutations affecting the same
gene. Ng et al. sequenced the exomes of four individuals
with Miller syndrome [14] and four individuals with
Freeman Sheldon syndrome [15] to identify the subset
of genes mutated in all individuals in each group. In
both studies, mutations in the remaining genes were fil-
tered against dbSNP and variants detected in 8 indivi-
duals from the HapMap project in order to eliminate
neutral human variation. Using this strategy, Ng et al.
were able to identify DHODH, encoding the enzyme
dihydroorotate dehydrogenase, as the causal gene under-
lying the four Miller syndrome exomes and MYH3,
encoding myosin-3, as the gene underlying the four
Freeman Sheldon syndrome exomes. MYH3 had pre-
viously been identified as the gene underlying Freeman
Sheldon syndrome via careful selection of candidate cau-
sal genes for sequencing based on similarity to other
Mendelian disorders with known genetic causes [16].
The work by Ng et al. demonstrated that a data-driven
approach can be useful in identifying disease genes
when there is no a priori list of candidate genes.
We postulated that it should be possible to identify
causal genes on the basis of enrichment for functional
mutations across disease exomes without filtering out
common variants first. Our reasoning was that enrich-
ment for functional mutations in a gene underlying a
common phenotype would provide a stronger signal
than functional mutations occurring in genes unrelated
to the phenotype. To test this hypothesis, we applied
our supervised machine learning-based method for pre-
dicting functional mutations to the variants observed in
the four Miller syndrome exomes and three of the four
Freeman Sheldon syndrome exomes described by Ng et
al. Our Variant Effect Scoring Tool (VEST) was trained
on a positive class of missense variants from the Human
Gene Mutation Database [17] (2012v2) and a negative
class of common missense variants detected in the
Exome Sequencing Project population [18]. VEST per-
formed well at identifying functional mutations in care-
ful benchmark experiments, with an area under the
Receiver Operating Characteristic of 0.92. One difference
between VEST and other existing methods for predicting
functional mutations is that VEST uses a statistical
hypothesis testing framework to assign p-values to pre-
dictions. In order to identify the causal genes, we aggre-
gated VEST p-values for all mutations by gene across all
disease exomes to create a gene-level statistic. Ranking
genes based on this statistic placed both MYH3 and
DHODH among the top 2 candidate causal genes.
Our gene prioritization approach differs from current
statistical methods for gene burden testing (reviewed in
[19,20]) in that we do not require a control population to
prioritize genes, although a matched control population,
if available, is useful for eliminating genes that are artifac-
tually significant as a result of sequencing and variant
calling errors. In addition, we show that the causal genes
can be identified without including allele frequency infor-
mation, although we expect that using allele frequency
information to filter the list of variants detected in exome
sequencing should make it easier to detect disease genes.
The effectiveness of gene burden algorithms is often
evaluated on the basis of statistical power to detect simu-
lated disease genes [21]. We evaluated our gene score
using this approach by simulating disease genes over a
range of parameters representative of real exome sequen-
cing data. We also performed simulations to evaluate the
potential consequences of VEST misclassification error
for correct disease gene prioritization. The results of the
simulations support the potential of our p-value-based
gene score to correctly identify Mendelian disease genes
using VEST functional predictions.
Results and discussion
VEST
The Variant Effect Scoring Tool (VEST) is a new method
for prioritizing missense mutations that alter protein activ-
ity. VEST uses a supervised machine learning algorithm,
Random Forest [22,23], to identify likely functional mis-
sense mutations. The training set is a positive class of mis-
sense variants from the Human Gene Mutation Database
and a negative class of common missense variants detected
in the Exome Sequencing Project (ESP) population.
Carter et al. BMC Genomics 2013, 14(Suppl 3):S3
http://www.biomedcentral.com/1471-2164/14/S3/S3
Page 2 of 16
An allele frequency of 1% or higher is considered common
for this work. All mutations are described by a set of 86
quantitative features.
Although the VEST training set is designed to identify
missense mutations that alter protein activity, its construc-
tion includes the additional context of selective difference
between disease and common variants. The disease class
from HGMD is enriched for variants under purifying
selection, whereas the neutral class from ESP common
variants includes variants under positive selection in the
human population in addition to truly neutral variants
[24]. If we assume that the VEST classifier can generalize
to mutations not in its training set, it should be able to
take a set of variants from a sequenced exome and priori-
tize functional mutations which are similar to disease
mutations over those which are similar to neutral muta-
tions or to functional mutations under positive selection.
VEST performance
In our experiments, VEST is able to generalize well, when
applied to mutations outside of its training set. We esti-
mate VEST generalization error stringently, using gene-
holdout cross-validation, similar to Capriotti et al. [25].
We believe that gene-holdout cross-validation helps con-
trol bias in generalization error estimates. Although the
features used to describe each mutation do not explicitly
contain gene level features, we expect to see greater corre-
lation between feature vectors for mutations in the same
gene relative to feature vectors for mutations in different
genes. Thus, by placing all mutations occurring in the
same gene into the same cross-validation partition, we
prevent the possibility of overestimating VEST perfor-
mance based on the elevated correlation between muta-
tions in the same gene. We quantify VEST’s performance
with a Receiver Operator Characteristic (ROC) [26] and a
Precision-Recall (PR) curve [27] (Figure 1). The area-
under-the-curve (AUC) statistic for these curves provides
a simple measure to summarize classifier performance.
VEST achieves an ROC AUC of 0.92, and at a VEST score
of 0.5 over 80% of the disease class mutations are correctly
classified whereas fewer than 20% of the neutral class
mutations are misclassified as functional.
We compared VEST to two popular methods for pre-
dicting functional mutations, SIFT 4.0 [4] and PolyPhen2
[8] using a simple holdout strategy to achieve an
unbiased comparison. The holdout strategy is necessary
to ensure that trained classifiers do not have an unfair
advantage in predicting benchmark set mutation class
membership as can occur when benchmark mutations
are included in the classifier training set. PolyPhen2 uses
supervised machine learning to train a classifier, while
SIFT4.0 does not. It was therefore necessary to design a
benchmark set that did not include any mutations in the
PolyPhen training set. Once again, we assumed that a
higher correlation between the feature vectors of
mutations in the same gene could lead to an advantage
for correctly predicting mutation class, so we constructed
our benchmark set such that only mutations in genes
that had no mutations in the PolyPhen2 classifier training
set were selected for the benchmark set.
PolyPhen2 provides two trained classifiers, HumDiv
and HumVar, for evaluating missense mutations. Hum-
Div is recommended for assessing rare alleles detected in
exome sequencing, while HumVar is recommended for
identifying variants underlying Mendelian disorders.
Therefore, in order to compare VEST to PolyPhen2, we
created two benchmark datasets, one to be used for com-
parison to the HumDiv classifier and the other for com-
parison to the HumVar classifier (Table 1). To ensure
that VEST did not have an unfair advantage, the VEST
classifiers used for benchmarking were then trained only
on the mutations from the training set remaining after
benchmark set construction. All classifiers (SIFT, Poly-
Phen2 and VEST) were used to score the benchmark set
mutations. Both PolyPhen2.0 and SIFT4.0 were unable to
score a subset of the benchmark mutations (Table 2), so
a direct comparison of classifier performance was only
possible on the subset of benchmark mutations scored by
all three methods. Results of the benchmark comparison
are shown in Figure 2 and described in Table 3.
Predicting functional mutations with VEST
VEST assigns variants a score between 0 and 1, where 1
indicates a confident prediction of a functional mutation.
We use a statistical hypothesis testing framework to
assess the significance of each score and adjust for multi-
ple testing as described previously [28]. Briefly, a set of
missense mutations representative of neutral human var-
iation provide a null model for testing the null hypothesis
that a given VEST score indicates a neutral mutation. If
the VEST score falls into the right tail (since large VEST
scores indicate a prediction of disease) we can uses the
null model to assess the probability of a neutral mutation
from our null model receiving a VEST score of the same
magnitude by chance. In general we expect to make a
large number of comparisons to the null distribution
because the number of missense mutations detected in
exome sequencing is large, therefore we estimate a false
discovery rate (FDR) cutoff for each p-vale using the Ben-
jamini-Hochberg method [29]. The p-value and FDR
associated with each mutation can be used to determine
a score cutoff for accepting a functional prediction. The
precise cutoff is subjective, allowing the user to deter-
mine an acceptable tradeoff between the number of can-
didate functional mutations identified, and the estimated
rate of false positive predictions. For this work, we mod-
eled neutral missense mutations using common variants
(AF ≥ 1%) observed in the 1000 Genomes Project [30],
and used the VEST score distribution for these mutations
to estimate p-values.
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Feature selection
We attempted to improve VEST classifier performance
using feature selection to remove features that were
uninformative for discriminating between disease and
neutral mutation classes. The predictive power of indivi-
dual features was assessed using mutual information
(MI), which provides a measure of the amount by which
the knowledge provided by the feature decreases the
uncertainty about the mutation class label [31]. To
acquire an unbiased estimate of improved performance,
we partitioned the training set into 3 parts: one for esti-
mating mutual information for the 86 features, one for
training a classifier with selected featuers, and one for
evaluating the resulting change in classifier performance.
We selected 47 features based on a threshold of MI ≥
0.001 bits. Using only the 47 selected features for classi-
fier training gave a slight boost to sensitivity, but reduced
classifier specificity (ROC AUC = 0.94 PR AUC = 0.89).
MI thresholds of MI ≥ 0 bits and MI ≥ 0.01 bits were
also tested (ROC AUC = 0.81 PR AUC = 0.72 and ROC
AUC = 0.94 PR AUC = 0.88 respectively). Based on these
findings, we elected to use the full set of 86 features for
VEST classifier construction.
Gene prioritization in Mendelian Disorders
Mendelian exome processing
We acquired raw DNA sequence reads for seven Mende-
lian disease exomes from dbGaP [32], four Miller syn-
drome exomes and three Freeman-Sheldon syndrome
exomes. Read mapping and variant calling were per-
formed as described in Methods. Results of variant call-
ing are described in Table 4. The numbers of variants
and mutated genes we found in these exomes are slightly
smaller than the numbers reported in the original publi-
cations. This difference was due to the variant calling
pipeline we used, which differs from that used in the ori-
ginal publications. In addition, we used a phred-quality
cutoff ≥ 30, similar to that used in the Freeman Sheldon
syndrome study, whereas the original Miller syndrome
study used a cutoff ≥ 20.
Mendelian exome variant scoring
We mapped variants detected in the four Miller syn-
drome exomes and the three Freeman Sheldon syndrome
exomes onto proteins. Variants that resulted in an amino
acid substitution were grouped into missense mutations
and truncating mutations. For this work, four types of
mutation were considered truncating: single nucleotide
Figure 1 VEST Classifier performance. Receiver Operating Characteristic (left) and precision-recall curve (right) for VEST were constructed using
5-fold gene holdout cross validation on the VEST training set. The AUC statistics for these two curves were both 0.92 indicating that the VEST
classifier has good sensitivity and specificity for identifying mutations with functional consequences for protein activity.
Table 1 Dataset composition.
Class Training set Benchmark test set Benchmark training set
Disease 47724 32841 14883
Neutral 45818 31018 14800
The VEST training set comprises a balanced number of disease-causing and
neutral missense mutations. In order to compare VEST performance to other
methods, the VEST training set was divided into a benchmark test set for
evaluating methods, and a benchmark training set, used for training a VEST
classifier for unbiased comparison.
Table 2 Benchmark mutation coverage.
Benchmark
Method Disease Neutral
VEST 100% 100%
PolyPhen2 89% 88%
SIFT4.0 57% 94%
All 3 51% 84%
Percentage of the benchmark test set mutations that could be scored by each
of the methods compared.
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Figure 2 Comparison of VEST with popular methods PolyPhen2 and SIFT4.0. Receiver Operating Characteristic (left) and precision-recall curve
(right) for VEST (A), PolyPhen2 (B) and SIFT4.0 (C). The color bar for SIFT is reversed since a low SIFT score corresponds to positive class prediction. ROC
AUC is 0.92, 0.85, 0.84 for VEST, PolyPhen2 and SIFT respectively. PR AUC is 0.88, 0.76, 0.72 for VEST, PolyPhen2 and SIFT respectively.
Table 3 Classifier performance. Classifier performance on the benchmark test set. Area under the curve (AUC)
statistics for Receiver Operating Characteristics and Precision-Recall curves are shown
Performance on benchmark Performance on benchmark (subset scored by all methods)
Method ROC AUC PR AUC ROC AUC PR AUC
VEST 0.912 0.919 0.917 0.884
PolyPhen2 0.857 0.840 0.854 0.762
SIFT4.0 0.835 0.715 0.838 0.724
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changes resulting in nonsense and nonstop mutations,
frameshift mutations, and deletions eliminating a splice
site. Variants resulting in silent changes or in-frame
insertions and deletions were discarded. Missense muta-
tions detected in each exome were scored with VEST.
Truncating mutations were not initially considered since
VEST is designed specifically for missense mutations. For
the purpose of identifying DHODH and MYH3 from the
missense mutations detected in the disease exomes, we
trained two custom VEST classifiers. The first classifier
used a training set filtered to eliminate all MYH3 muta-
tions; and the second was filtered to eliminate all
DHODH mutations. Using these classifiers to score mis-
sense mutations ensured that DHODH and MYH3 muta-
tions did not receive artificially significant VEST scores
because of overlap with the training set. This was neces-
sary to ensure an unbiased assessment of our gene score
for identifying candidate causal genes.
Selecting a method to aggregate VEST scores by gene
We tested three methods for aggregating VEST mutation
scores into gene scores: the average VEST score, Fisher’s
method [33] and Stouffer’s Z-score [34]. We compared
each method on the basis of gene rank of the causal
genes underlying the four Miller exomes (DHODH) and
the three Freeman Sheldon exomes (MYH3). We found
that Stouffer’s Z most consistently ranked the causal
genes highest. Fisher’s method aggregates the log2 of the
p-value of each mutation and hence low p-values make a
larger contribution to the final score than higher
p-values. As a consequence, genes with a large number of
mutations of which only a small number receive func-
tional VEST scores can still receive small p-values, lead-
ing to a larger list of candidate disease genes. Stouffer’s
method appears to provide the best gene prioritization
for Mendelian disease genes. Both methods for aggregat-
ing p-values outperformed the average VEST score
approach (Table 5).
Accounting for Mendelian disease models
We first attempted to identify DHODH and MYH3 by
simply considering all mutations detected across the dis-
ease exomes. Since both Miller syndrome and Freeman
Sheldon syndrome are Mendelian disorders, we also tried
pre-filtering the list of mutated genes using possible dis-
ease models. For this work, we considered autosomal
dominant and autosomal recessive models. Patterns of
Mendelian disease segregation in families can provide
clues as to the appropriate disease model. In the absence
of this information, a simple autosomal dominant model
represents a conservative choice since all genes harboring
at least a single mutation in all disease exomes must be
considered. Since Miller syndrome had previously been
observed to have an autosomal recessive pattern of
inheritance, we also tried a recessive model where only
genes harboring at least two mutations in each exome
were considered. Using a disease model to filter the list
of candidate genes improved the ranks of each mutation
(Table 5), but the recessive model, while reducing the
number of genes taken into consideration from 2258 to
1267, did not improve our ability to detect DHODH.
Some Mendelian disorders display locus heterogeneity,
where the same disorder in two or more individuals
results from mutations in distinct genes. We first
assessed the potential of our gene score to identify multi-
ple disease genes in a setting of locus heterogeneity by
combining the three Freeman Sheldon syndrome exomes
with the four Miller syndrome exomes prior to ranking
mutated genes. When all seven exomes were considered
simultaneously and any gene mutated in at least two indi-
viduals was scored, we found that MYH3 ranked second
and DHODH ranked fourth out of 5561 candidate genes.
Next we tried combining one Freeman Sheldon syn-
drome exome with all four Miller syndrome exomes, and
vice versa. In these cases, the disease gene in the majority
of exomes ranked in the top 3 genes while the disease
gene from the single exome ranked anywhere from 26 to
710 (out of ~6400 genes) depending on the magnitude of
the VEST score for the disease mutation (Table 6).
Finally, we performed simulations to estimate the power
of our approach to identify disease genes at different
degrees of locus heterogeneity. We find that locus het-
erogeneity does reduce power to detect disease genes
that are mutated in only a small fraction of disease
exomes (Figure 3). In our simulations, disease genes
p-values are smallest when the Z-score sampled for the
Table 4 Variant calling results.
Exome SNV calls cSNVs InDel calls Missense Truncating Mutated genes Common mutated genes
Miller Syndrome 1 18256 14744 391 6569 98 4213 2258
Miller Syndrome 2 17403 14438 381 6409 113 4096 2258
Miller Syndrome 3 18367 14907 428 6575 106 4210 2258
Miller Syndrome 4 17074 14166 373 6377 111 4059 2258
Freeman Sheldon 1 19957 15383 567 6891 139 4310 2314
Freeman Sheldon 2 18929 14730 502 6618 123 4151 2314
Freeman Sheldon 3 15125 12361 371 5485 112 3675 2314
Summary of variant calling results for four Miller syndrome exomes and three Freeman Sheldon syndrome exomes.
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disease mutation is large, and when the number of non-
disease mutations observed in the disease gene is low,
suggesting that disease genes that are not frequently
mutated and harbor disease mutations of strong effect
will be more easily detected.
Including truncating mutations
The VEST classifier is specifically designed to prioritize
missense mutations. However, truncating mutations also
alter protein activity and contribute to human genetic
disease. Each truncating mutation t was assigned a score
[1 − AF(t)] ∗ max(M), (1)
where AF is allele frequency andM represents the VEST
scores of all missense mutations observed in the
sequenced exomes. Thus, low frequency truncating events
received high VEST scores. We then estimated p-values
for the truncating mutation scores using the 1000 Gen-
omes null model. We then recalculated gene scores using
p-values for both missense and truncating mutations.
When truncating mutations were included, DHODH and
MYH3 dropped in rank among prioritized genes to 3 and
12 respectively (Table 5). This is not surprising, since a
number of the truncating mutations are present at low fre-
quency or result from what appear to be private mutations
and therefore receive VEST scores close to 1. It should be
noted that indel calling is difficult [35] and indel calling
algorithms are thought to have a high false positive rate
for calling frameshift events [36]. The possibility that
novel frameshift mutations detected by variant calling
pipelines may be enriched for false mutations suggests
that it will be important to develop a better scoring algo-
rithm for truncating mutations when including them for
gene prioritization.
Effect of null distribution on gene score
The choice of null model for assessing VEST score signifi-
cance can directly influence the gene score. This is
because the gene score is estimated from p-values, and the
magnitude and dispersion of the p-values for a set of
Table 5 Gene rank and p-value assigned to causal gene in two Mendelian disorders.
Disorder/Gene Mean VEST Rank Mean VEST score Fisher Rank Fisher p-value Stouffer Rank Stouffer p-value
All genes
Miller syndrome/DHODH 112 0.71 7 11.6e-07 3 1.9e-06
Freeman Sheldon syndrome/MYH3 124 0.67 3 3.7e-14 3 9.3e-07
Dominant model
Miller syndrome/DHODH 15 0.71 5 4.4e-08 2 1.9e-06
Freeman Sheldon syndrome/MYH3 12 0.67 3 3.7e-14 2 9.3e-07
Recessive model
Miller syndrome/DHODH 12 0.71 4 9.8e-06 2 1.9e-06
Dominant model including truncating
Miller syndrome/DHODH 11 0.75 10 7.0e-11 3 2.5e-08
Freeman Sheldon syndrome/MYH3 19 0.67 10 3.8e-14 12 9.3e-07
Recessive model including truncating
Miller syndrome/DHODH 9 0.75 10 7.14e-10 3 2.5e-08
Ranks and p-values for the genes underlying Miller syndrome and Freeman Sheldon syndrome for three gene lists: all genes harboring missense mutations,
genes with a missense mutation in at least one copy in all disease exomes (dominant model), and genes with a missense mutation in both copies in all disease
exomes (recessive model). Genes were ranked using two scoring methods, Fisher’s method and Stouffer’s Z score.
Table 6 Mendelian disease gene detection under locus heterogeneity.
MYH3 mutation VEST scores Fisher Rank (MYH3) Stouffer Rank (MYH3) Fisher Rank (DHODH) Stouffer Rank (DHODH)
0.045, 0.993 5 6 8 3
0.045, 0.963 144 710 7 3
0.045, 0.963 142 695 7 3
DHODH mutation VEST scores Fisher Rank (MYH3) Stouffer Rank (MYH3) Fisher Rank (DHODH) Stouffer Rank
(DHODH)
0.33, 0.98, 0.859 26 27 3 3
0.33, 0.952, 0.523 53 118 3 3
0.33, 0.98, 0.859 26 27 4 3
0.33, 0.636 582 554 3 3
Gene ranks for DHODH and MYH3 using the Fisher and Stouffer gene score methods when Freeman Sheldon syndrome exomes and Miller syndrome exomes are
combined as one versus all. The top half of the table shows the results of combining individual Freeman Sheldon exomes with all four Miller syndrome exomes,
while the bottom half shows the results of combining each Miller syndrome exome with all three Freeman Sheldon syndrome exomes. The first column reports
VEST scores for missense mutations in the causal gene in the single exome.
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VEST scores depend on the shape of the null distribution
used to assess score significance. VEST score distributions
for three different empirical null models are shown in
Figure 4: one generated from common variants observed in
the 1000 Genomes Project, one comprising neutral poly-
morphisms from the SwissProt variant pages [37], and
another consisting of variants from the Complete Geno-
mics 69 exome diversity panel [38]. We find that using
different null models to estimate VEST score p-values does
influence the ranking of MYH3 and DHODH among the
candidate disease genes (Table 7). The 1000 Genomes Pro-
ject null model looks similar to the Complete Genomics
null model even though the two datasets were sequenced
at very different coverage (a range of 2X to 4X for 1000
Genomes versus a range of 51X to 89X for Complete
Genomics). This suggests that coverage depth is unlikely to
have introduced systematic bias into the null model when
only variants at allele frequencies ≥ 1% are considered.
Interestingly, the null model based on SwissProt poly-
morphisms showed more enrichment for functional VEST
scores than the other null models. This suggests that some
SwissProt polymorphisms may not be functionally neutral,
or that VEST misclassifies a subset of them because of
some difference between the SwissProt polymorphisms
Figure 3 Power to detect disease genes in simulated cases of locus heterogeneity. Estimated power to detect disease genes in the
presence of locus heterogeneity when A) seven, three and one exomes share disease genes B) three, two and one exomes share disease genes
C) ten and one exomes share disease genes D) each of four exomes results from a distinct disease gene. In each case gene p-values acquired
using both Fisher’s and Stouffer’s methods are compared. Power is shown for raw p-values as well as Benjamini-Hochberg adjusted p-values. The
height of each bar corresponds to the number of simulations in which the gene received a p-value or adjusted p-value <0.05.
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and the common variants used to train the VEST
classifier.
Assessing the power of the gene score to detect disease
genes
We attempted to quantify the power of our gene score
for identifying disease genes using simulations implemen-
ted in R [39]. For our simulations, we represent each
mutation by a Z-score. Neutral mutation Z-scores are
sampled from the standard normal distribution, while
disease mutation Z-scores are sampled from a standard
normal distribution with a mean shift. We simulate a
population of 1000 disease genes by sampling mutations
from both distributions and then calculating a gene level
p-value using Stouffer’s Z-score or Fisher’s method. In
order to use Fisher’s method, Z-scores are first converted
to p-values. We estimate the power of each gene score as
the fraction of simulated disease genes receiving a
p-value <0.05. We assessed the sensitivity of the two
gene scoring approaches to three parameters of the simu-
lation: the mean shift between the null and disease
Z-score distributions (the effect size), the total number of
mutations per gene, and the fraction of the mutations
Figure 4 Comparison of VEST score distribution for three empirical null models. Density plots created from VEST score distributions for
three empirical null models representing neutral human missense variation. Null model mutations were filtered to remove overlap with the VEST
training set, then scored with the VEST classifier. The Swissprot-based null shows an enrichment for large VEST scores in the right tail, indicating
predicted functional mutations.
Table 7 MYH3 and DHODH rankings using different null models.
Gene FisherRank FisherP FisherBHFDR StoufferRank StoufferP StoufferBHFDR
Swissprot null model
DHODH 4 3.8e-05 0.05 2 0.001 1.00
MYH3 5 1.7e-05 0.05 4 0.021 1.00
1000 genomes null model
DHODH 5 4.4e-08 0.05 2 1.9e-06 0.05
MYH3 3 3.8e-14 0.05 2 9.3e-07 0.05
Complete genomics null model
DHODH 5 4.6e-08 0.05 2 1.9e-06 0.05
MYH3 15 2.0e-06 0.05 5 2.4e-03 1.00
Ranks of MYH3 and DHODH differ slightly when different null models are used to estimate p-values for VEST mutation scores.
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that are sampled from the disease Z-score distribution.
The mean shift between null and Z-score distributions is
a proxy for the difference in the mean VEST scores for
neutral mutations versus functional mutations. The effect
of varying these parameters on power to identify disease
genes is shown in Figure 5. Power is plotted on the
y-axis, and the total number of mutations per gene is
plotted on the x-axis. Each plot represents a different
effect size (0.5,1.0,1.5,2.0 from left to right). The family of
curves in each plot represents a population of genes
simulated with a different fraction of mutations sampled
from the disease Z-score distribution. Z-score distribu-
tions generated from the unbiased gene-holdout cross-
validation VEST scores for the training set suggest that
we can expect an effect size greater than 1.7 for Mende-
lian disease mutations.
Disease gene identification is clearly sensitive to the
effect size of disease mutations. The proportion of muta-
tions observed in a gene that are disease related is also a
key determinant of power, therefore it may be easier to
detect disease genes if mutations are pre-filtered to
remove common mutations unlikely to contribute to dis-
ease. Power increases as the number of mutations
increases, which may indicate that increasing the number
of disease exomes will result in improved ability to identify
causal genes. We also assessed the effect of VEST misclas-
sification error on the power to identify disease genes. We
selected four points from the ROC curve constructed to
estimate VEST generalization error. Each point represents
a reasonable tradeoff between classifier sensitivity and spe-
cificity (TPR = 60%, FPR = 5%; TPR = 70%, FPR = 10%;
TPR = 80%, FPR = 15%; TPR = 90%, FPR = 25% where
TPR=True Positive Rate and FPR = False Positive Rate).
We repeated our power simulation at each of these mis-
classification rates. The number of disease mutations
sampled for each gene was multiplied by true positive
rates of 90%, 80%, 70% and 60% to simulate the effects of
misclassification. The results of these simulations are
shown in Figure 6. Each row of plots represents the power
to detect disease genes at different VEST true positive
rates. Misclassification error does reduce the power to
detect disease genes, but only marginally. The largest
decreases in power occur at a true positive rate of 60%
and are on the order of 20%. In general, if both the effect
size and the fraction of disease mutations are small, dis-
ease genes will be difficult to detect regardless of misclassi-
fication. If effect size and fraction of disease mutations are
large, the effects of misclassification are negligible.
Contrasting gene scores in Freeman Sheldon syndrome and
Miller syndrome
Mutations detected in exome sequencing include artifac-
tual mutations resulting from DNA sequencing and var-
iant calling errors. These false variants can confound the
search for true disease causing mutations/genes. Since
sequencing errors are not associated with disease pheno-
type, it is often possible to filter them out by comparing
to a control population. Specifically, systematic sequen-
cing error should be apparent because it will result in
similar rates of false mutations in both disease exomes
and controls, while the true causal mutations should be
present in only the disease exomes. To effectively use this
approach, both disease exomes and control exomes must
be processed using the same DNA sequencing technolo-
gies and variant calling pipelines [40].
Since both the Freeman Sheldon syndrome exomes and
the Miller syndrome exomes were sequenced using the
same technology, we hypothesized that genes not causally
related to these phenotypes might have received similar
gene scores in both groups. If so, this could enable us to
remove from consideration any genes that received sig-
nificant scores due to false mutations resulting from
DNA sequencing and variant calling errors. In order to
prioritize genes that behave differently in the two groups
of exomes, we fit a linear model using gene score
p-values. When genes are required to meet the criteria
for a dominant disorder (at least one mutation per
exome), only 1640 genes were common to the two
groups, including MYH3 but not DHODH. MYH3
Figure 5 Sensitivity of gene score to mutation count and fraction of functional mutations at different effect sizes. Power to detect
disease genes was estimated using simulations in R. Mutation counts and fraction of functional mutations were varied at four different effect
sizes (0.5, 1.0, 1.5 and 2.0). A distinct plot represents the results of the simulation for each effect size. The legend on the top right shows the
fraction of disease mutations simulated in each gene.
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received the largest negative residual with the linear
model, identifying it as being enriched for functional
mutations in Freeman Sheldon syndrome relative to
Miller syndrome (Table 8). Furthermore, many of the top
scoring genes that were initially prioritized due to false
mutations, including CDC27, CTBP1, and OR4C3
[41-43] receive residuals close to 0 indicating that they
harbor a similar profile of mutations in both exome sets
and are therefore unlikely to be causally related to either
disorder.
Conclusions
Whole exome sequencing studies for the characterization
of disease variation uncover thousands of candidate causal
mutations per individual. In this work, we have developed
a new, accessible tool, VEST, for prioritizing functional
mutations among those detected through exome sequen-
cing. We show that simple aggregation of VEST prediction
p-values across genes and disease exomes can be used to
identify disease genes in Mendelian disorders. In two Men-
delian disorders with known causation, our gene score
places the causal genes among the top 5 candidate genes
with no prior filtering to reduce the list of candidates, and
in the top 2 when only genes that meet Mendelian criteria
are considered. This serves as proof of principle that bioin-
formatics methods for scoring mutations can be used
directly for disease gene discovery in exome sequencing
studies, through a simple application that could easily be
automated. Disease related mutations and genes are more
difficult to identify in complex disorders because there is
less concentration of causal variants in individual genes,
disease causing variants often have variable penetrance
and environmental factors can greatly modify disease risk.
The approach described here may nonetheless help to
Figure 6 Sensitivity of gene score to VEST classification error. Power simulations were repeated with an additional parameter: VEST true
positive rate (TPR). Four TPRs were selected based on VEST generalization error estimates. A set of simulation is shown for each of the four
points (60%, 70%, 80% and 90%). As expected, power to detect disease genes decreases as the TPR decreases.
Table 8 Top genes in Freeman Sheldon syndrome
exomes after comparison to Miller syndrome Exomes.
Rank GeneSymbol Residuals FSS p-value Miller p-value
1 MYH3 -0.92 0.000 0.946
2 MYH7B -0.72 0.032 0.745
3 GCN1L1 -0.28 0.049 0.247
4 MLL3 -0.23 0.032 0.164
5 POTED -0.22 0.031 0.159
6 FRG2C -0.20 0.013 0.108
7 KCNJ18 -0.17 0.001 0.058
8 SLC12A3 -0.13 0.044 0.061
9 BCLAF1 -0.12 0.005 0.008
10 OR4C3 -0.12 0.002 0.004
After comparing gene scores in Freeman Sheldon syndrome (FSS) exomes to
Miller syndrome exomes using a linear model, genes are re-sorted on
residuals. Here, small negative residuals indicate genes that were more
significant in Freeman Sheldon syndrome exomes relative to Miller syndrome
exomes.
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identify genes, or pathways consisting of multiple genes,
that are enriched for functional mutations among indivi-
duals with complex disorders. Our method is distinct from
existing methods that rely on differing allele frequencies in
cases versus controls to identify causal genes. Allele fre-
quencies are not required in our approach, but can be used
to filter variants prior to VEST scoring and p-value aggre-
gation. In addition, while matched controls are useful for
removing genes that are functionally impaired but not
associated with the specific phenotype, our approach is still
useful when controls are not available. Further experiments
are planned to determine the power of our approach for
identifying genes involved in complex disease.
Methods
Read mapping and variant calling
Four Miller syndrome exomes [14] and three Freeman-
Sheldon syndrome exomes [15] were acquired in the form
of short read archive (SRA) files from dbGaP [32] (Miller
syndrome study accession: phs000244.v1.p1 Freeman Shel-
don syndrome study accesion: phs000204.v1.p1) and con-
verted to fastq format using fastq-dump version 2.1.12
from the SRA Toolkit http://www.ncbi.nlm.nih.gov/
Traces/sra/sra.cgi?cmd=show&f=software&m=softwar-
e&s=software. The Miller syndrome and Freeman-Sheldon
syndrome 76bp single end Illumina Genome Analyzer
reads were pre-processed using the fastx toolkit [44] to
only include reads with a Phred-like consensus quality 20
for 50 percent of the bases. The reads were then mapped
to the reference genome (UCSC hg19) using the Burrows-
Wheeler Aligner (BWA v0.6.1) [45]. The resulting outputs
were sorted and indexed using samtools [46]. Unmapped
reads and duplicates were then removed using the
Bamtools [47] and picard software http://picard.source-
forge.net. The aligned positions with a Phred-like consen-
sus quality value 30 were retained for downstream variant
calling. The Genome Analysis Toolkit (v1.6-11-g3b2fab9)
then realigned intervals around potential indels and
re-calibrated the base quality scores [48,49]. GATK Analy-
sis was limited to the human exome from the list of
RefSeq exons plus an additional 10 bp at each splice site.
GATK’s Unified Genotyper module performed variant
calling resulting in variant call format (VCF) files. The
resulting VCF files (v4.1) were filtered through GATK’s
variant filter module using hard filter settings. SNP filter-
ing removed calls based of the following criteria: (i) MQ0
≥ 4&&((MQ0 = (1.0 * DP)) >0.1); (ii) QUAL <30.0 || QD
<5.0 || H Run >5 || SB >-0.10); and (iii) cluster window
size 10. Phasing for the SNP calls was determined using
the GATK ReadBackPhasing algorithm restricted to the
exon ranges at a phasing quality threshold of 20.0. Indel
filtering removed calls based on the following criteria
(i) MQ0 ≥ 4&&((MQ0/(1.0 * DP)) >0.1); (ii) SB ≥ -1.0;
(iii) QUAL <10.
Variant mapping
Single nucleotide variants were mapped onto coding
regions using the SNVBox genomic coordinate mapping
tool and designated as missense, nonsense, nonstop or
silent. Indels were mapped onto RefSeq proteins using the
refGene table in the UCSC Genome Browser [50]. Indels
were designated inframe, frameshift or splice altering.
Variant scores
VEST classifier training
A Random Forest classifier (ntrees = 1000, mtry = 9) was
trained on 47724 missense mutations directly implicated
in human inherited disease from the Human Gene Muta-
tion Database (HGMD Professional v2012.2), and 45818
likely neutral missense mutations from the Exome
Sequencing Project (ESP6500 accessed 07/2012) using
parf Parallel Random Forest software http://code.google.
com/p/parf/. Each mutation was described by a vector of
86 quantitative features available through the SNVBox
database [51]. HGMD disease mutations were filtered so
as to exclude polymorphisms, low-confidence disease
mutations and common variants (AF ≥ 1%). This filtering
strategy removed 3592 polymorphisms, 4739 low confi-
dence mutations and 492 common variants. An addi-
tional 14181 variants that did not cause missense
changes were also removed. Twenty-three of the remain-
ing variants did not have a RefSeq accession associated
with the variant, 321 consisted of different genomic
events that resulted in the identical missense mutation
and 47 could not be annotated with features from the
SNVBox because the transcript identifier was not sup-
ported. ESP6500 mutations were filtered to remove rare
variants (AF <1%), and any mutations occurring at the
same codon as an HGMD disease mutation were
dropped. Removing overlap with HGMD resulted in
689823 missense variants, only 46303 of which were pre-
sent at (AF <1%) and mapped onto a RefSeq NM identi-
fier. An additional 485 ESP6500 mutations could not be
annotated with features from SNVBox because the tran-
script identifier was not supported.
Feature selection
The training set was partitioned in to 3 approximately
equal parts, each with a balanced number of mutations
from HGMD and ESP6500. The three partitions were con-
strained such a that all mutations in the same gene were
included in the same partition. We used mutual informa-
tion between feature values and class labels estimated from
the first partition to select all features that provided at least
0.01 bits, 0.001 bits or any positive amount of information
about the label. We then trained a VEST classifier using
partition 2 and the subset of features selected using parti-
tion 1. The 3rd partition was scored with the classifier to
determine whether classifier performance improved rela-
tive to a classifier trained using all the features.
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Estimating classifier generalization error
To assess VEST’s generalization error, we used 5-fold
cross-validation. The VEST training set was divided into
5 partitions such that each partition contained a balanced
number of disease and neutral mutations. All mutations
occurring in the same gene were constrained to occur in
the same partition in order to avoid overly optimistic
estimates of the generalization error. We did not con-
strain homologous genes to occur in the same partition.
Receiver Operator Characteristic (ROC) and Precision-
Recall (PR) curves were constructed from the predicted
class labels and the AUC statistic was used as a measure
of classifier performance.
Benchmark Construction and Benchmark Variant Scoring
with SIFT4.0 and PolyPhen2
For benchmark set construction, we downloaded the
PolyPhen2.2.2 training set release dated December 2011
(http://genetics.bwh.harvard.edu/pph2/dokuwiki/down-
loads). HUGO gene symbols were associated with
PolyPhen2 training set variants using a local mirror of the
UCSC Genome Browser [52]. The VEST training set was
then partitioned into a benchmark test set and a bench-
mark training set. Any mutation in the VEST training set
that occurred in a gene represented in the PolyPhen2
training set was placed into the benchmark training set,
and all remaining mutations were placed in the bench-
mark test set. More HGMD disease mutations overlapped
the PolyPhen2 training set than neutral mutations, so
additional mutations were removed from the benchmark
test partition and placed in the benchmark training parti-
tion until a balanced number of each class was reached.
To ensure unbiased benchmarking, we moved all muta-
tions in the same gene together such that no gene was
split across the benchmark training and test partitions.
A VEST classifier was trained on the benchmark training
set and used to score the benchmark test set. Genomic
coordinates in hg19 for the benchmark test set missense
mutations were submitted to the PolyPhen2 batch webser-
ver http://genetics.bwh.harvard.edu/pph2/bgi.shtml as well
as to a local installation of SIFT4.0. Since PolyPhen2 offers
2 trained classifiers, HumDiv and HumVar, this procedure
was repeated twice.
Statistical hypothesis testing framework and empirical null
distributions
VEST assigns missense mutations a score between 0 and
1, representing the fraction of decision trees in the Ran-
dom Forest that voted for the disease mutation class. We
used an empirical null model to estimate p-values for each
missense mutation based on VEST scores. We constructed
three empirical null distributions consisting of CHASM
scores for 13639 polymorphisms from the Swissprot var-
iant pages, 28509 variants from the 1000 Genomes Project
with AF ≥ 1%, and 3421 high quality variants from the
Complete Genomics diversity panel with allele count ≥5in
the 69 individuals (Complete Genomics Assembly Soft-
ware Version 2.0, CGATools version 1.6). P-values for
each variant were estimated as the fraction of null distri-
bution VEST scores greater than or equal to the VEST
score of the variant. Each empirical null was filtered to
remove overlap with the VEST training set. When scoring
multiple missense mutations (n >10), false discovery rates
were estimated using the Benjamini-Hochberg method.
Gene scores
Parametric approaches
We tested two parametric methods commonly used in
meta-analysis: Fisher’s Method and Stouffer’S Z-score.
Both methods require that p-values are uniformly distribu-
ted under the null hypothesis. Fisher’s method aggregates
p-values on the log scale (Eq. 2) such that very small
p-values make a larger contribution to the statistic and
can be thought of as an ‘at least’ approach since small p-
values will make a larger contribution to the statistic than
large p-values. The statistic based on the k aggregated p-
values is c2 distributed with 2k degrees of freedom, provid-
ing an overall p-value.
X 2 = −2
k∑
i=1
ln(pi) (2)
Stouffer’s Z-score first converts p-values for each variant
to the equivalent z-score on the standard normal distribu-
tion. These z-scores are then aggregated (Eq. 3) and the
cumulative Z-score is used to get a new meta p-value.
Z =
∑k
i=1 Zi√
k
(3)
Truncating mutation scores
Scores for truncating mutations were calculated as 1-allele
frequency multiplied by the maximum VEST score for any
missense mutation. For this work, four types of mutation
were considered truncating: single nucleotide changes
resulting in nonsense and nonstop mutations, frameshift
mutations, and deletions eliminating a splice site. We used
the maximum allele frequency for the variant in the 1000
Genomes dataset, the Exome Sequencing Project Eur-
opean-American dataset or the Exome Sequencing Project
African-American dataset.
Simulations
We assessed the sensitivity of the gene scoring methods to
three parameters: the magnitude of VEST scores for func-
tional mutations, the number of mutations per gene and
the fraction of mutations per gene using power simula-
tions. We generated a population of 1000 disease genes by
randomly selecting Z-scores from a null distribution (the
standard normal distribution) and an alternative distribu-
tion (the standard normal distribution with a mean shift)
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to represent neutral and functional mutations respectively.
We used effect size to represent the magnitude of VEST
scores. Here, effect size is the distance between the mean
of a Z-score distribution for neutral mutations and the
mean of a Z-score distribution for functional mutations. If
disease mutations receive strong functional scores with
VEST, the distances between the means of these distribu-
tions will be large, whereas for modestly scoring functional
mutations, the distance will be smaller. We tested mean
shifts of 0.5. 1.0, 1.5 and 2.0 and varied the number of
mutations from 0 to 50. The fraction of mutations
sampled from the alternative distribution was varied from
20% to 100% at intervals of 20%. Z-scores sampled for
each gene were aggregated according to Stouffer’s method,
or converted to p-values then aggregated according to
Fisher’s method, and the resulting statistic was used to
assign the gene a p-value. Power was estimated as the frac-
tion of the disease genes that received a p-value <0.05. To
simulate the effect of variant misclassification on the gene
score power to detect disease genes, we simulated genes
with misclassification rates based on VEST generalization
error estimates. We selected four points along the ROC
curve generated using 5-fold gene holdout cross validation
of the VEST classifier (TPR = 60%, FPR = 5%; TPR = 70%,
FPR = 10%; TPR = 80%, FPR = 15%; TPR = 90%, FPR =
25%)(see Methods: Estimating classifier generalization
error).
We tested the sensitivity of our gene scoring method to
locus heterogeneity by simulating a set of normal exomes
and introducing disease mutations into distinct genes in
subsets of the exomes. In order to ensure that simulated
exomes reciprocated the variability in mutation count
per gene observed in real sequencing data, we used gene-
specific distributions of mutation counts from the Free-
man Sheldon syndrome and Miller syndrome exomes.
Approximately 7000 distinct genes were observed to harbor
mutations when all seven real exomes were considered. To
simulate a new exome, we sampled a gene-specific muta-
tion count for each of the ~7000 distinct genes and then,
for each gene, generated that number of non-disease asso-
ciated mutations by sampling Z-scores from the standard
normal distribution. Next, we selected a gene in each simu-
lated exome to represent a Mendelian disease gene, and
sampled an additional Z-score from a mean-shifted stan-
dard normal distribution to represent a disease mutation.
For recessive cases, two additional mutations were gener-
ated per disease gene. Mutation scores were then aggre-
gated for each gene, resulting in a gene level p-value and a
gene rank. We ran each simulation 100 times, and varied
the number of exomes created, the number of disease
genes, and the disease model (dominant versus recessive).
Estimating effect size from the VEST training set
In order to estimate the expected effect size for functional
mutations versus neutral mutations, we determined
Z-score distributions for the disease and neutral classes of
the VEST training set using VEST scores acquired by 5-
fold gene holdout cross-validation. The 1000 Genomes
null model was used to estimate a p-value for each muta-
tion. The p-values were then converted to Z-scores and
the distributions for disease and neutral class mutations
compared. We found that the distance between the means
of the two distributions was 1.85, with the mean of the
neutral class Z-scores at 0.12 and the mean of the disease
class Z-scores at -1.73.
Mendelian gene scores
For each Mendelian disorder dataset, we pooled all var-
iants detected in the exomes, then grouped all variants by
gene. Many Mendelian disorders are monogenic, so we
removed genes that were not mutated in all case exomes.
This assumption can be relaxed to include all genes or
genes mutated in at least a subset of disease exomes if
locus heterogeneity is suspected. Miller syndrome has
previously been observed to follow a recessive inheritance
pattern; therefore we also filtered the Miller syndrome
data to remove genes that did not show evidence of
mutation in both copies in all exomes. Evidence that
both copies of a gene were mutated included homozy-
gous mutations, or two heterozygous mutations in the
same gene. Where possible, phasing information was
used to rule out multiple heterozygous mutations if they
occurred in the same copy of the gene.
Contrasting gene scores across groups
We used R statistical software to fit a linear model to 1640
genes that were scored in both Freeman Sheldon syn-
drome and Miller syndrome exomes. Freeman Sheldon
syndrome gene p-values generated with the Stouffer
Z-score method were used as the dependent variable, and
Miller syndrome gene p-values generated with the Stouffer
Z-score were used as the independent variable. The resi-
duals resulting from the linear model were used to assess
which of the top ranked genes were more likely to result
from sequencing artifacts either due to the sequencing
technology or because of properties of the reference gen-
ome. A large positive residual indicated p-values that were
larger in Freeman Sheldon syndrome than would have
been expected by the corresponding p-values in the Miller
syndrome data while large negative residual indicated
p-values in Freeman Sheldon syndrome that were much
smaller than would have been expected in Miller data.
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